Adenosine A(2A) receptor agonists increase Fos-like immunoreactivity in mesolimbic areas

Brain Research

Volumn 759, Issue 1, 1997, Pages 41-49

  Pinna, Annalisa ^a   Wardas, Jadwiga ^b   Cristalli, Gloria ^c   Morelli, Micaela ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b INSTITUTE OF PHARMACOLOGY   (Poland)

^c UNIVERSITY OF CAMERINO   (Italy)

Author keywords

A(2A) receptors; Antipsychotic; Dopamine; Early gene; Nucleus accumbens; Striatum

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE; ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR AGONIST; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; NEUROLEPTIC AGENT; OXIDOPAMINE; QUINPIROLE; 2 HEXYNYLADENOSINE 5' N ETHYLCARBOXAMIDE; 2-HEXYNYLADENOSINE-5'-N-ETHYLCARBOXAMIDE; 5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; DRUG DERIVATIVE; PHENETHYLAMINE DERIVATIVE; PROTEIN C FOS; PURINE RECEPTOR; PYRIMIDINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; BEHAVIOR; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; EMOTION; EXTRAPYRAMIDAL SYMPTOM; GENE EXPRESSION; GENE EXPRESSION REGULATION; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LIMBIC CORTEX; MALE; NERVE PROJECTION; NONHUMAN; NUCLEUS ACCUMBENS; ONCOGENE C FOS; PRIORITY JOURNAL; RAT; SEPTUM NUCLEUS; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; LIMBIC SYSTEM; METABOLISM; SPRAGUE DAWLEY RAT;

ADENOSINE; ADENOSINE-5'-(N-ETHYLCARBOXAMIDE); ANIMALS; DOPAMINE AGONISTS; IMMUNOHISTOCHEMISTRY; LIMBIC SYSTEM; MALE; OXIDOPAMINE; PHENETHYLAMINES; PROTO-ONCOGENE PROTEINS C-FOS; PYRIMIDINES; QUINPIROLE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, PURINERGIC; RECEPTORS, PURINERGIC P1; TRIAZOLES;

EID: 0030610483     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(97)00214-X     Document Type: Article

References (53)

1. Abbracchio M.P., Colombo F., Di Luca M., Zaratin P., Cattabeni F. Adenosine modulates the dopaminergic function in the nigro-striatal system by interaction with striatal dopamine dependent adenylate cyclase. Pharmacol. Res. Commun. 19:1987;275-286.
2. Alexander S.P., Reddington M. The cellular localization of adenosine receptors in rat neostriatum. Neuroscience. 28:1989;645-651.
3. 2a receptors in the nucleus accumbens mediate locomotor depression. Brain Res. Bull. 31:1993;397-404.
4. Boegman R.J., Vincent S.R. Involvement of adenosine and glutamate receptors in the induction of c-fos in the striatum by haloperidol. Synapse. 22:1996;70-77.
5. Brown S.J., Gill R., Evenden J.L., Iversen D.S., Richardson P.J. Striatal A2 receptor regulates apomorphine-induced turning in rats with unilateral dopamine denervation. Psychopharmacology. 103:1991;78-82.
6. Cristalli G., Eleuteri A., Vittori S., Volpini R., Lohse M.J., Klotz K.-N. 2-Alkynyl derivatives of adenosine and adenosine-5′-N-ethyluronamide as selective agonists at A2 adenosine receptors. J. Med. Chem. 35:1992;1179-1183.
7. Deutch A.Y., Lee M., Iadarola M.J. Regionally specific effects of atypical antipsychotic drugs on striatal Fos expression: The nucleus accumbens shell as a locus of antispychotic action. Mol. Cell. Neurosci. 3:1992;332-341.
8. Dragunow M., Faull R.L.M. The use of c-fos as a metabolic marker in neuronal pathway tracing. J. Neurosci. Methods. 29:1989;261-265.
9. 2 dopamine receptor antagonists induce Fos and related proteins in rat striatal neurons. Neuroscience. 37:1990;287-294.
10. Durcan M.J., Morgan P.F. NECA-induced hypomotility in mice: evidence for a predominantly central site of action. Pharmacol. Biochem. Behav. 32:1989;487-490.
11. 2 receptor involvement in the hypomotility effects of adenosine analogues in mice. Eur. J. Pharmacol. 168:1989;285-290.
12. 2 receptors in the neostriatum. Brain Res. 594:1992;124-130.
13. Ferré S., Fuxe K., von Euler G., Johansson B., Fredholm B.B. Adenosine-dopamine interactions in the brain. Neuroscience. 51:1992;501-512.
14. Ferré S., O'Connor W.T., Fuxe K., Ungerstedt U. The striopallidal neuron: a main locus for adenosine-dopamine interactions in the brain. J. Neurosci. 13:1993;5402-5406.
15. 2 receptors in the ventral striopallidal system. Implications for the treatment of schizophrenia. Neuroscience. 63:1994;765-773.
16. Fibiger H.C. Neuroanatomical targets of neuroleptic drugs as revealed by Fos immunochemistry. J. Clin. Psychiatry. 55:1994;33-36.
17. 2 dopamine receptors in rat striatum. Mol. Brain Res. 14:1992;186-195.
18. Fredholm B.B. Purinoceptors in the nervous system. Pharmacol. Toxicol. 76:1995;228-239.
19. 2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science. 250:1990;1429-1432.
20. Guo N., Klitenick M.A., Tham C.-S., Fibiger H.C. Receptor mechanisms mediating clozapine-induced c-fos expression in the forebrain. Neuroscience. 65:1995;747-756.
21. Heimer L., de Olmos J., Alheid G.F., Zaborszky L. 'Perestroika' in the basal forebrain: opening the border between neurology and psychiatry. Prog. Brain Res. 87:1991;109-165.
22. 2 agonist binding in the rat brain. Brain Res. 690:1995;34-40.
23. 2 selective adenosine receptor agonist with preferential hypotensive activity. J. Pharmacol. Exp. Ther. 251:1989;47-56.
24. 3H]CGS 21680. Eur. J. Pharmacol. 168:1989;243-246.
25. 2 receptors in rat brain. J. Pharmacol. Exp. Ther. 251:1989;888-893.
26. 3H]CGS 21680 to rat brain using autoradiography. Neuropharmacology. 34:1995;393-403.
27. 2 receptor interaction in animal models of schizophrenia. Eur. J. Pharmacol. 295:1996;147-154.
28. 3 dopamine receptors in rat brain and pituitary gland: A quantitative autoradiographic study. J. Pharmacol. Exp. Ther. 264:1993;991-996.
29. 3H]hydroxy-N,N-di-n-propyl-2-aminotetralin. Proc. Natl. Acad. Sci. USA. 89:1992;8155-8159.
30. MacGibbon G.A., Lawlor P.A., Bravo R., Dragunow M. Clozapine and haloperidol produce a differential pattern of immediate early gene expression in rat caudate-putamen, nucleus accumbens, lateral septum and islands of Calleja. Mol. Brain Res. 23:1994;21-32.
31. 2 receptor interaction in globus pallidus. Synapse. 22:1996;32-138.
32. Miller J. Induction of c-fos mRNA expression in rat striatum by neuroleptic drugs. J. Neurochem. 54:1990;1453-1455.
33. Monopoli A., Conti A., Zocchi C., Casati G., Volpini R., Cristalli G., Ongini E. Pharmacology of the new selective A2a adenosine receptor agonist 2-hexynyl-5′-N-ethylcarboxamidoadenosine. Arzneim.-Forsch./Drug Res. 44(II)(12):1994;1296-1304.
34. 2 receptors in unilaterally 6-hydroxydopamine-lesioned rats. Eur. J. Pharmacol. 251:1994;21-25.
35. 2 receptors stimulate c-fos expression in striatal neurons of 6-hydroxydopamine-lesioned rats. Neuroscience. 67:1995;49-55.
36. Morgan J.I., Curran T. Proto-oncogene transcription factors and epilepsy. Trends Pharmacol. Sci. 12:1991;343-345.
37. Nguyen T.V., Kosofsky B.E., Birnbaum R., Cohen B.M., Hyman S.E. Differential expression of c-fos and Zif268 in rat striatum after haloperidol, clozapine, and amphetamine. Proc. Natl. Acad. Sci. USA. 89:1992;4270-4274.
38. 2a receptors in rat striatum: implications for the mechanism and the treatment of tardive dyskinesia. J. Neurochem. 65:1995;2057-2064.
39. G. Paxinos and C. Watson, The Rat Brain in Stereotaxic Coordinates, Academic Press, Sydney, 1986.
40. L.J. Pellegrino, A.S. Pellegrino and A.J. Cushman, A Stereotaxis Atlas of the Rat Brain, Plenum Press, New York, 1979.
41. 1 agonists in dopamine denervated rats. Eur. J. Neurosci. 8:1996;1176-1181.
42. 2 dopamine-dependent activation of Fos in the striatopallidal pathway. Neuroscience. 68:1995;721-728.
43. Popoli P., Pèzzola A., Reggio R., Caporali M.G., Scotti de Carolis A. CGS 21680 antagonizes motor hyperactivity in a rat model of Huntington's disease. Eur. J. Pharmacol. 257:1994;R5-R6.
44. Premont J., Perez M., Blanc G., Tassin J.-P., Thierry A., Herve D., Bockaert J. Adenosine-sensitive adenylate cyclase in rat brain homogenates: Kinetic characteristics, specificity, topographical subcellular and cellular distribution. Mol. Pharmacol. 16:1979;790-804.
45. Robertson G.S., Fibiger H. Neuroleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine. Neuroscience. 46:1992;315-328.
46. Robertson G.S., Matsumura H., Fibiger H.C. Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J. Pharmacol. Exp. Ther. 271:1994;1058-1066.
47. Sagar S.M., Sharp F.R., Curran T. Expression of c-fos protein in brain: Metabolic mapping at the cellular level. Science. 240:1988;1328-1331.
48. 2 receptors regulate the gene expression of striatopallidal and striatonigral neurons. J. Neurosci. 13:1993;1080-1087.
49. Van Calker D., Muller M., Hamprecht B. Adenosine regulates via two different types of receptors the accumulation of cyclic AMP in cultured brain cells. J. Neurochem. 33:1979;999-1005.
50. 2 receptor regulation of apomorphine-induced turning in rats with unilateral striatal dopamine denervation. Psychopharmacology. 111:1993;383-388.
51. 2 (long-form) receptor co-transfected mouse fibroblast cell lines: studies on intracellular calcium levels. Neuroscience. 68:1995;729-736.
52. Zahm D.S., Brog J.S. On the significance of subterritories in the 'accumbens' part of the rat ventral striatum. Neuroscience. 50:1992;751-767.
53. 2a adenosine receptor antagonist. J. Pharmacol. Exp. Ther. 276:1996;389-404.